報價延遲最少15分鐘:2026/08/01 19:49 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.49 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.64/0.83
|
|
企業價值
349.47M
|
| 資產負債 |
|
每股賬面淨值
3.45
|
| 現金流量 |
|
現金流量率
0.08
|
| 損益表 |
|
收益
95.02M
|
|
每股收益
1.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US. |
